Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (EPRX) will host a virtual Analyst Day on November 13, 2026, and participate in four upcoming investor and industry conferences. The Analyst Day presentation, scheduled for 8:30am ET, will discuss EP-104GI for eosinophilic esophagitis.
Management will attend the Craig Hallum Biotech Catalyst Virtual Conference on October 22, BIO-Europe in Cologne on November 9–11, the Stifel Healthcare Conference in New York on November 10–12, and the Jefferies Global Healthcare Conference in London on November 16–19, 2026. Participation includes presentations, fireside chats and one-on-one meetings, depending on the event.
Eupraxia Pharmaceuticals (EPRX) reached its 120-patient enrollment target for the Phase 2b portion of RESOLVE investigating EP-104GI for eosinophilic esophagitis. The 120th patient was enrolled and treated on October 12, 2026. The blinded, placebo-controlled study compares 120mg and 160mg doses with vehicle control. Periodic reviews of unblinded data confirmed that the planned sample size needs no adjustment to support the study’s statistical objectives.
Across the open-label Phase 1b/2a and placebo-controlled Phase 2b portions, over 3,000 injections of EP-104GI or vehicle have been administered with no treatment-related serious adverse events. Eupraxia expects an interim analysis in December 2026, covering symptoms, tissue findings and safety in the first 60 Phase 2b patients to reach six months, alongside data at other follow-up timepoints. The company also plans additional Phase 1b/2a data in the coming months.
Eupraxia Pharmaceuticals (EPRX) will present three abstracts on its ongoing RESOLVE trial of EP-104GI at upcoming gastroenterology conferences in October 2026.
The presentations are scheduled for October 12 at ACG in Nashville and October 18–19 at UEG in Barcelona. They cover swallowing difficulties and tissue changes in eosinophilic esophagitis, an inflammatory condition affecting the esophagus. The Phase 1b/2a study is open-label and evaluates escalating doses. The randomized, placebo-controlled Phase 2b study is recruiting at 120mg and 160mg doses. Eupraxia expects interim Phase 2b data in December 2026 and plans additional Phase 1b/2a disclosures in the coming months.
Eupraxia Pharmaceuticals (EPRX) reported 52-week responses to EP-104GI in the highest-dose cohort of its ongoing Phase 1b/2a RESOLVE trial for eosinophilic esophagitis.
After a single administration, 66% (2 of 3) of Cohort 9 patients maintained clinical remission at 52 weeks. Across cohorts 5–9, the rate was 64% (9/14). Cohort 9's mean swallowing-symptom score reduction was 3.0 at both 36 and 52 weeks; Cohort 8b's was 3.3 at 36 weeks. Cohort 8b also showed mean reductions in tissue-damage extent and severity scores of 0.26 and 0.27, respectively, at 36 weeks.
The open-label study reported no treatment-emergent or procedure-related serious adverse events, oral or throat candidiasis, adrenal insufficiency or glucose derangement. The randomized, placebo-controlled Phase 2b study is recruiting at 120mg and 160mg doses; Eupraxia expects interim data in December 2026.
Eupraxia Pharmaceuticals (EPRX) has transferred its common share listing to the Nasdaq Global Select Market, with trading already commenced under the same ticker on Nasdaq and the Toronto Stock Exchange.
The shares were previously listed on the Nasdaq Capital Market, and the company states that no action is required from shareholders in connection with the transfer. The Nasdaq Global Select Market is described as Nasdaq’s highest tier, reserved for issuers that meet its most stringent financial, liquidity and governance standards.
Eupraxia also plans to participate in three New York–based investor conferences in September 2026, featuring a fireside chat, company presentation and one‑on‑one meetings with investors.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) reported new Phase 1b/2a RESOLVE trial data for EP-104GI in eosinophilic esophagitis, including the first detailed analysis of odynophagia (painful swallowing) symptom scores.
Among Cohorts 7-9 (20 injections; 80–160 mg total dose), the proportion of patients with moderate or severe odynophagia fell from 62% at baseline to 31% at weeks 2–12 and 25% at weeks 24, 36 and 52; severe odynophagia, reported by 23% at baseline, was absent at weeks 24 and 52. Patients with no odynophagia increased from 15% at baseline to 50% at week 52.
For dysphagia (difficulty swallowing), moderate or severe cases declined from 77% at baseline to 54% at week 12 and 25% at weeks 24 and 52; severe dysphagia (31% at baseline) was not seen at weeks 24 and 52. According to Eupraxia, over 130 patients have received EP-104GI or placebo across RESOLVE (over 2,000 injection sites) with no treatment-emergent or procedure-related serious adverse events and no concerns regarding mean glucose or cortisol levels. The randomized, placebo-controlled Phase 2b portion is recruiting 120 mg and 160 mg doses, with an interim readout expected in Q4 2026.
Eupraxia Pharmaceuticals (NASDAQ:EPRX, TSX:EPRX) reported a Q2 2026 net loss of $14.5 million, compared with $8.7 million a year earlier, mainly from higher research and development and general and administrative expenses linked to expanding its RESOLVE Part 2 trial in eosinophilic esophagitis (EoE).
The company held $52.4 million in cash and cash equivalents and $81.2 million in short-term investments at June 30, 2026, up from an aggregate $80.6 million at the end of Q4 2025, and expects its cash to fund operations into the second half of 2028.
New RESOLVE trial data presented at DDW showed improved inflammation and fibrosis and 66% symptom remission at week 36 in the highest-dose cohort (2 of 3 patients). Eupraxia also strengthened its executive team and board, and shifted to a Vancouver–Seattle operational hub structure.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced key executive and organizational changes to support its transition toward later-stage clinical and commercial development. Effective July 13, 2026, Dr. Jeff Millard joins as Executive Vice President, Technical Operations, bringing about 25 years of experience in technical operations, CMC and regulatory strategy, and will lead these functions for Eupraxia with a focus on EP104GI.
Dr. Alex Therien, who joined in November 2025, becomes Executive Vice President, Research & Development, taking leadership of R&D to drive portfolio expansion. The company has shifted its operational hubs from Victoria to Vancouver and Seattle, with key clinical, manufacturing and commercial leadership, including the CEO, based in Seattle. As part of this transition, Chief Scientific and Operating Officer Amanda Malone, based in Victoria, stepped down effective July 10, 2026. Eupraxia highlights its Phase 1b/2 RESOLVE trial of EP-104GI in EoE, a completed Phase 2b SPRINGBOARD trial of EP-104IAR in knee osteoarthritis that met its primary endpoint, and its broader pipeline using its Diffusphere™ drug delivery platform.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) appointed Robert Bazemore, Amy Pott and Dr. Helen Thackray to its Board of Directors.
Their backgrounds span 30+ years in novel medicine development, late-stage clinical programs, global product launches and commercialization, supporting upcoming milestones for EP-104GI and expansion of Eupraxia’s gastroenterology-focused pipeline and Diffusphere™ platform.
Eupraxia Pharmaceuticals (TSX/NASDAQ:EPRX) reported voting results from its June 18, 2026 Annual General Meeting. All seven management-nominated directors were elected, each receiving over 91% of votes cast, and KPMG LLP was re-appointed as auditor for the coming year.
The company highlighted its Diffusphere™ drug-delivery platform, its Phase 1b/2 RESOLVE trial of EP-104GI for EoE, and the completed Phase 2b SPRINGBOARD trial of EP-104IAR for knee osteoarthritis, which met its primary endpoint and three of four secondary endpoints.